160 related articles for article (PubMed ID: 32131953)
1. [Immunotherapy and Pharmaceutical Care for Non-small-cell Lung Cancer Complicated with Hyperthyroidism:Report of One Case].
Shen Z; Cao GW; Wang J; Pan J; Shi AM; Zhu Z
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Feb; 42(1):132-135. PubMed ID: 32131953
[TBL] [Abstract][Full Text] [Related]
2. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
3. Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer.
Dong J; Li B; Zhou Q; Huang D
J Evid Based Med; 2018 Nov; 11(4):278-287. PubMed ID: 30444051
[TBL] [Abstract][Full Text] [Related]
4. Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy.
Li M; Gan L; Song A; Xue J; Lu Y
Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):323-330. PubMed ID: 30826426
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in Lung Cancer: A New Age in Cancer Treatment.
Corrales L; Scilla K; Caglevic C; Miller K; Oliveira J; Rolfo C
Adv Exp Med Biol; 2018; 995():65-95. PubMed ID: 30539506
[TBL] [Abstract][Full Text] [Related]
6. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
Wang S; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
[TBL] [Abstract][Full Text] [Related]
7. [Not Available].
Fabre E; Pécuchet N; Cadranel J
Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
[TBL] [Abstract][Full Text] [Related]
8. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
[TBL] [Abstract][Full Text] [Related]
9. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
10. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
11. PD-1-targeted immunotherapy: recent clinical findings.
Brahmer JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
[No Abstract] [Full Text] [Related]
12. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
13. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
Pennell NA
Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
[TBL] [Abstract][Full Text] [Related]
14. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
Socinski MA
Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
[No Abstract] [Full Text] [Related]
15. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
Pabani A; Butts CA
Curr Oncol; 2018 Jun; 25(Suppl 1):S94-S102. PubMed ID: 29910652
[TBL] [Abstract][Full Text] [Related]
16. Monitoring immunotherapy outcomes with circulating tumor DNA.
Goldberg SB; Patel AA
Immunotherapy; 2018 Sep; 10(12):1023-1025. PubMed ID: 30185140
[No Abstract] [Full Text] [Related]
17. Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
Sholl LM; Aisner DL; Allen TC; Beasley MB; Borczuk AC; Cagle PT; Capelozzi V; Dacic S; Hariri L; Kerr KM; Lantuejoul S; Mino-Kenudson M; Raparia K; Rekhtman N; Roy-Chowdhuri S; Thunnissen E; Tsao MS; Yatabe Y;
Arch Pathol Lab Med; 2016 Apr; 140(4):341-4. PubMed ID: 26780537
[TBL] [Abstract][Full Text] [Related]
18. New discoveries in lung cancer highlighted at conference.
Printz C
Cancer; 2014 Jun; 120(11):1598-9. PubMed ID: 24844819
[No Abstract] [Full Text] [Related]
19. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
20. [Current challenges with PD-L1 testing for immunotherapy biomarkers in non-small cell lung cancer].
Li Y; Chen J
Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):585-589. PubMed ID: 31422587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
